openPR Logo
Press release

Opioid Withdrawal Syndrome Market Key Players, Share and Forecast Outlook

08-12-2025 12:45 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Exactitiude Consultancy

Opioid Withdrawal Syndrome Market

Opioid Withdrawal Syndrome Market

Introduction
The Opioid Withdrawal Syndrome (OWS) Market is gaining increasing attention as the opioid epidemic continues to escalate worldwide. OWS occurs when chronic opioid users abruptly reduce or stop usage, leading to severe physical and psychological symptoms. With opioid misuse rising and governments prioritizing addiction treatment, demand for both pharmacological and behavioral withdrawal management solutions is growing. Innovations in long-acting formulations, expansion of community-based programs, and increased integration of telehealth into addiction care are reshaping the market landscape.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/70805

Market Overview - Key Highlights
• Market Size 2024: USD 2.45 billion
• Forecasted Market Size 2034: USD 4.60 billion
• CAGR (2024-2034): ~6.5%
• Key Growth Drivers: Rising opioid addiction rates, expanding medication-assisted treatment (MAT) programs, and supportive government policies.
• Challenges: Social stigma, patient relapse rates, and lack of treatment access in rural and low-income regions.
• Leading Players: Indivior PLC, Alkermes plc, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Camurus AB, Hikma Pharmaceuticals PLC, Braeburn Inc.

Market Segmentation
By Treatment Type
• Medication-Assisted Treatment (Methadone, Buprenorphine, Naltrexone)
• Symptomatic Medications (Clonidine, Lofexidine, NSAIDs)
• Behavioral Therapy & Counseling
• Inpatient Detox Programs
• Outpatient Withdrawal Management

By Route of Administration
• Oral
• Injectable
• Transdermal

By End-User
• Hospitals
• Specialty Addiction Treatment Centers
• Community Health Clinics
• Telehealth Platforms

Segmentation Summary:
Medication-assisted treatment is the dominant segment, particularly buprenorphine-based therapies due to their efficacy in reducing withdrawal symptoms and preventing relapse. Telehealth platforms are gaining popularity for delivering counseling and prescription services remotely.

Get Your Exclusive Offer with up to 10% Discount:
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=70805

Regional Analysis
• North America:
Largest market share due to high opioid use prevalence, established MAT programs, and strong government funding for withdrawal management.
• Europe:
Significant growth supported by national harm reduction strategies, public healthcare coverage, and expansion of rehabilitation centers.
• Asia-Pacific:
Fastest-growing region, driven by rising opioid misuse, growing investment in addiction treatment infrastructure, and increasing awareness campaigns.
• Middle East & Africa:
Gradual adoption supported by government-led rehabilitation initiatives in select countries.
• Latin America:
Steady growth led by Brazil and Mexico, with expanding community-based withdrawal programs.
Regional Summary:
While North America currently dominates, Asia-Pacific will record the highest CAGR due to rapid healthcare modernization and greater government involvement in addiction treatment.

Market Dynamics
Key Growth Drivers:
• Increasing global opioid dependence.
• Growth in MAT adoption across both public and private healthcare systems.
• Expanding telemedicine-based addiction care services.

Key Challenges:
• Persistent social stigma around opioid dependence.
• Limited access to treatment in rural areas.
• Risk of relapse after withdrawal treatment.

Latest Trends:
• Launch of long-acting buprenorphine injections for improved patient adherence.
• Integration of digital health tools for symptom monitoring.
• Partnerships between pharmaceutical companies and NGOs to expand MAT access.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/70805/opioid-withdrawal-syndrome-market

Competitive Landscape
Major Players:
1. Indivior PLC
2. Alkermes plc
3. Pfizer Inc.
4. Teva Pharmaceutical Industries Ltd.
5. Camurus AB
6. Hikma Pharmaceuticals PLC
7. Braeburn Inc.
8. Viatris Inc.
9. Opiant Pharmaceuticals Inc.
10. Sandoz International GmbH

Competition Summary:
The market is innovation-driven, with companies focusing on long-acting drug delivery systems, affordable MAT solutions, and strategic collaborations to improve treatment access and retention.

Conclusion
The Opioid Withdrawal Syndrome Market is on a growth trajectory through 2034, fueled by rising opioid dependence, the expansion of MAT programs, and increasing acceptance of telehealth-based withdrawal care. Players focusing on patient-centric, affordable, and long-acting therapies will have a competitive edge in addressing this ongoing global crisis.

This report is also available in the following languages : Japanese (オピオイド離脱症候群市場), Korean (오피오이드 금단 증후군 시장), Chinese (阿片类药物戒断综合症市场), French (Marché du syndrome de sevrage aux opioïdes), German (Markt für Opioid-Entzugssyndrom), and Italian (Mercato della sindrome da astinenza da oppioidi), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/70805

Our More Report:

Drone In a Box
https://exactitudeconsultancy.com/reports/65794/drone-in-a-box-market

Drone Taxis
https://exactitudeconsultancy.com/reports/65796/drone-taxis-market

Drone Warefare
https://exactitudeconsultancy.com/reports/65798/drone-warefare-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Opioid Withdrawal Syndrome Market Key Players, Share and Forecast Outlook here

News-ID: 4141899 • Views:

More Releases from Exactitiude Consultancy

Metastatic Castration-Sensitive Prostate Cancer Market Size And Global Industry Forecast 2034
Metastatic Castration-Sensitive Prostate Cancer Market Size And Global Industry …
Introduction The Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market is witnessing strong growth as improved screening programs, advanced imaging technologies, and innovative treatment combinations reshape the clinical landscape. mCSPC refers to prostate cancer that has spread beyond the prostate gland but still responds to androgen deprivation therapy (ADT). The introduction of novel hormonal agents, targeted therapies, and expanded use of chemotherapy in combination regimens has significantly improved patient survival outcomes, creating lucrative
Opioid-Induced Respiratory Depression Market Industry Analysis by Size, Share, Growth, Sourcing Strategy, Scope, Demand and Forecast to 2034
Opioid-Induced Respiratory Depression Market Industry Analysis by Size, Share, G …
Introduction The Opioid-Induced Respiratory Depression (OIRD) Market is expanding as opioid prescription rates remain high and awareness grows about the risks of respiratory suppression linked to these medications. OIRD, a potentially fatal side effect of opioid use, can occur in post-operative pain management, chronic pain therapy, and illicit opioid abuse. Increasing adoption of advanced respiratory monitoring systems, wider access to reversal agents like naloxone, and innovations in opioid formulations with reduced
Alcohol Use Disorder Market Size, Share and Growth Report, 2034
Alcohol Use Disorder Market Size, Share and Growth Report, 2034
Introduction The Alcohol Use Disorder (AUD) Market is gaining momentum as awareness of substance use disorders increases and treatment accessibility improves worldwide. AUD, a chronic condition characterized by impaired control over alcohol consumption, remains a significant public health issue, contributing to liver disease, cardiovascular problems, mental health disorders, and premature mortality. With expanding rehabilitation services, the development of novel medications, and growing adoption of telehealth-based therapy models, the market is poised
Cerebral Palsy Market Size And Global Industry Forecast 2034
Cerebral Palsy Market Size And Global Industry Forecast 2034
Introduction The Cerebral Palsy (CP) Market is steadily expanding due to growing awareness, advancements in treatment approaches, and technological innovations in assistive devices. Cerebral palsy, a group of permanent movement disorders caused by brain damage before or during birth, remains the most common motor disability in children. While no cure exists, significant progress in pharmacological interventions, surgical techniques, and rehabilitation therapies is improving patient quality of life. Increasing investments in early

All 5 Releases


More Releases for Opioid

Rising Opioid Use For Pain Management Fuels Growth In Opioid-Induced Constipatio …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Opioid-Induced Constipation Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market size for treatment of opioid-induced constipation has seen a substantial growth recently. It is expected to escalate from a solid $1.78 billion in 2024 to an impressive $1.9 billion in 2025, exhibiting
Growing Number Of Opioid Addiction Cases: Strategic Insights Driving Opioid Use …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Opioid Use Disorder (OUD) Market Size By 2025? The market size for opioid use disorder (OUD) has experienced a quick expansion in the past few years. The growth is projected to rise from $3.96 billion in 2024 to $4.39 billion in 2025, boasting a compound
Key Influencer in the Opioid-Induced Constipation Treatment Market 2025: Rising …
What combination of drivers is leading to accelerated growth in the opioid-induced constipation treatment market? The rise in opioid administration for cancer and non-cancer pain is expected to drive the growth of the opioid-induced constipation (OIC) treatment market. Opioids are commonly used for managing moderate to severe pain, but they can cause constipation. OIC treatments are vital for improving the quality of life for patients on opioids, allowing them to maintain
Top Factor Driving Opioid Use Disorder (OUD) Market Growth in 2025: Growing Numb …
How Are the key drivers contributing to the expansion of the opioid use disorder (oud) market? The rise in instances of opioid dependency is set to fuel the expansion of the opioid use disorder (OUD) market. Opioid dependency defines a health concern marked by habitual and uncontrolled opioid consumption which negatively impacts health. These opioids can generate feelings of bliss and relief from pain, but continued usage often results in tolerance
What's Driving the Opioid-Induced Constipation Treatment Market 2025-2034: Risin …
What Are the Projections for the Size and Growth Rate of the Opioid-Induced Constipation Treatment Market? The market size for treatments of constipation caused by opioids has seen robust growth lately. The forecasted growth indicates an increase from $1.78 billion in 2024 to $1.9 billion in 2025, representing a compound annual growth rate (CAGR) of 7.0%. This past growth is associated with a growing elderly population, individualized treatments for OIC, the
MEDICAL MARIJUANA AND THE OPIOID CRISIS
Marijuana from the Cannabis plant is classified as a psychoactive drug used for medical or recreational purposes. Although it has been used for decades, in the U.S., it is still illegal under federal law to use and possess marijuana. Get PDF Sample Brochure of this report at: https://decisionmarketreports.com/request-sample/1247622 Nevertheless, at the state level, policies regarding the medical and recreational use of Cannabis vary greatly, and in many states conflict significantly with federal